Alaunos Therapeutics
- Country
- πΊπΈUnited States
- Ownership
- Public
- Employees
- 1
- Market Cap
- $4.4M
- Website
- http://www.alaunos.com
- Introduction
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
Clinical Trials
37
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (35 trials with phase data)β’ Click on a phase to view related trials
Long-Term Follow-up Study of Subjects Treated With Autologous T Cells Using the Sleeping Beauty System to Express TCRs
- Conditions
- Colorectal CancerPancreatic CancerNon-small Cell Lung CancerOvarian CancerAdenocarcinoma of LungAdenosquamous Cell Lung CancerOvary NeoplasmCholangiocarcinomaGynecologic CancerSquamous Cell Lung Cancer
- Interventions
- Biological: Neoantigen specific TCR-T cell drug product
- First Posted Date
- 2022-03-23
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 7
- Registration Number
- NCT05292859
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
- Conditions
- Ovary NeoplasmAdenosquamous Cell Lung CancerCholangiocarcinomaAdenocarcinoma of LungColorectal CancerPancreatic CancerOvarian CancerEndometrial CancerNon-small Cell Lung CancerOvarian Carcinoma
- First Posted Date
- 2022-01-18
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 180
- Registration Number
- NCT05194735
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors
- Conditions
- Colo-rectal CancerEndometrial CancerPancreas CancerOvarian CancerCholangiocarcinomaNon-small Cell Lung Cancer
- First Posted Date
- 2021-11-18
- Last Posted Date
- 2025-07-30
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 19
- Registration Number
- NCT05124743
- Locations
- πΊπΈ
MD Anderson Cancer Center, Houston, Texas, United States
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
- Conditions
- Glioblastoma
- Interventions
- First Posted Date
- 2019-07-02
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 40
- Registration Number
- NCT04006119
- Locations
- πΊπΈ
Cedars Sinai, Los Angeles, California, United States
πΊπΈUniversity of California - San Francisco, San Francisco, California, United States
πΊπΈBaptist MD Anderson Cancer Center, Jacksonville, Florida, United States
Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Alaunos Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT03679754
- Locations
- πΊπΈ
Cedars-Sinai Medical Center, Los Angeles, California, United States
πΊπΈNorthwestern Memorial Hospital, Chicago, Illinois, United States
πΊπΈNYU - Langone Health, New York, New York, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 8
- Next